Jump to main content
Jump to site search

Issue 38, 2018
Previous Article Next Article

Identification of substandard and falsified antimalarial pharmaceuticals chloroquine, doxycycline, and primaquine using surface-enhanced Raman scattering

Author affiliations

Abstract

Falsified antimalarial pharmaceuticals are a worldwide problem with negative public health implications. Here, we develop a surface-enhanced Raman scattering (SERS) protocol to recognize substandard and falsified antimalarial drugs present in commercially available tablets. After recording SERS spectra for pure chloroquine, primaquine, and doxycycline, SERS is used to measure these drugs formulated as active pharmaceutical ingredients (APIs) in the presence of common pharmaceutical caplet excipients. To demonstrate the viability of our approach, a red team study was also performed where low-quality and falsified formulations of all three drugs presented as unknowns were identified. These data in conjunction with promising results from a portable Raman spectrometer suggest that SERS is a viable technique for on-site analysis of drug quality.

Graphical abstract: Identification of substandard and falsified antimalarial pharmaceuticals chloroquine, doxycycline, and primaquine using surface-enhanced Raman scattering

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Jun 2018, accepted on 10 Sep 2018 and first published on 17 Sep 2018


Article type: Paper
DOI: 10.1039/C8AY01413B
Citation: Anal. Methods, 2018,10, 4718-4722
  •   Request permissions

    Identification of substandard and falsified antimalarial pharmaceuticals chloroquine, doxycycline, and primaquine using surface-enhanced Raman scattering

    E. C. Tackman, M. J. Trujillo, T. E. Lockwood, G. Merga, M. Lieberman and J. P. Camden, Anal. Methods, 2018, 10, 4718
    DOI: 10.1039/C8AY01413B

Search articles by author

Spotlight

Advertisements